Table 1.
Comparison of characteristics between patients with immunohistochemical staining data (IHC group, n = 41) and non-IHC group (n = 20). IHC: immunohistochemistry; CF: cisplatin plus 5-fluorouracil; PCF: paclitaxel plus CF; GC: gemcitabine plus cisplatin; Unfavorable group: hydronephrosis/hydroureter and/or pelvic nodal involvement; Favorable group: other than unfavorable group.
| Characteristics | No of Patients (%) | Fisher’s Exact Test or χ2 Test p-Value |
||
|---|---|---|---|---|
| Non-IHC Group (n = 20) | IHC Group (n = 41) | |||
| Sex | Male | 14 (70) | 25 (61) | 0.35 |
| Female | 6 (30) | 16 (39) | ||
| Age (years) | <70 | 16 (80) | 24 (59) | 0.084 |
| ≥70 | 4 (20) | 17 (41) | ||
| Clinical T stage | T2 | 19 (95) | 30 (73) | 0.083 |
| T3–T4a | 1 (5) | 11 (27) | ||
| Induction chemotherapy | CF | 4 (20) | 12 (29) | 0.78 |
| PCF | 5 (25) | 11 (27) | ||
| GC | 11 (55) | 18 (44) | ||
| Prognostic factors | Favorable group | 16 (80) | 33 (80) | 0.61 |
| Unfavorable group | 4 (20) | 8 (20) | ||